Baird lowered the firm’s price target on Revvity (RVTY) to $127 from $141 and keeps an Outperform rating on the shares. The firm upated its model ahead of its Q1 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target lowered to $120 from $140 at Bernstein
- Revvity price target lowered to $116 from $143 at BofA
- Revvity price target lowered to $110 from $140 at Barclays
- Revvity announces FDA approval for Auto-Pure 2400 liquid handling platform
- Revvity enters agreement with Genomics England for Generation Study collab